CASMED Gets FDA Approval For Fore-Sight Elite In Pediatric, Neonatal Patients

(RTTNews) - CAS Medical Systems Inc. (CASM) or CASMED announced receipt of an expanded label for its FORE-SIGHT ELITE oximeters from the U.S. Food and Drug Administration to include its new medium and small sensors for use with pediatric and neonatal patients.

The company also said that it sponsored a lunch symposium at the 37th Society for Cardiac Anesthesia Annual Meeting & Workshops held earlier this week in Washington, D.C. The hour-long symposium featured a panel of leading physicians discussing the clinical benefits of monitoring cerebral oxygenation in a broad variety of cardiac surgeries through the use of case studies, personal experience and the latest clinical evidence.

CASM closed Tuesday's trading at $1.37. In Wednesday's pre-market trading, the company's shares are up $0.10 or 7.41 percent to $1.45.